Haemonetics Corporation (NYSE: HAE), a medical technology company specializing in blood management and hospital technologies, closed at $119.47 on October 8, 2026, gaining $17.76, or 17.46%. The sharp advance lifted the company’s intraday market capitalization to approximately $5.44 billion, while its five-day performance reached 14.47%.
Haemonetics Stock Performance
Haemonetics opened at $115.00 and traded between $111.66 and $120.72 during the session. Its previous close was $101.71, making the latest increase a substantial one-day move.
Trading volume reached approximately 2.77 million shares, compared with an average volume of around 715,678 shares. The elevated activity accompanied the stock’s strong advance.
Haemonetics has a 52-week trading range of $48.17 to $121.00, placing its latest closing price close to the upper end of that range. Its trailing P/E ratio stands at 57.71, with trailing EPS of $2.07. The company’s five-year monthly beta is 0.61.
Blood Management and Hospital Technologies
Haemonetics provides medical technology solutions through its Plasma, Blood Center and Hospital segments. Its portfolio includes automated plasma collection systems, donor management software and supporting technologies designed to help plasma customers manage donors, operations and supply chains.
The company also offers NexSys PCS plasmapheresis equipment and related disposable products, as well as integrated information technology platforms for plasma collection operations.
Its donor management and operational systems include NexLynk DMS and Donor360 tools, which support donor administration and related workflows.
Hospital and Surgical Technology Portfolio
Haemonetics provides technologies used in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery and cancer surgery.
Its portfolio includes SavvyWire, a sensor-guided guidewire for transcatheter aortic valve replacement procedures, and OptoWire, a pressure guidewire used to measure fractional flow reserve and diastolic pressure ratio. The company also supplies fiber-optic sensor solutions for medical devices and other critical industrial applications.
Additional hospital products include the TEG 6s system, a cartridge-based viscoelastic analyzer used to assess a patient’s hemostasis, and TEG Manager software, which connects TEG analyzers across hospitals and provides clinicians with remote access to test results.
The company also offers Cell Saver Elite+, an autologous blood recovery system used in cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical and gynecological procedures.
Vascular Closure and Transfusion Management
Haemonetics’ product range includes VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL and VASCADE MVP. These products use a catheter-based delivery system and the natural clot-inducing properties of collagen for vascular closure procedures.
The company sells its products through a direct sales force and independent distributors, supporting its reach across healthcare institutions and other customers.
Leadership and Company Profile
Haemonetics is led by Christopher A. Simon, who serves as CEO, president and director. Other senior executives include CFO and Executive Vice President James C. D’Arecca, Executive Vice President and COO Frank W. Chan, Executive Vice President and General Counsel Michelle L. Basil, and Executive Vice President and Chief Commercial Officer Roy Galvin.
The company has approximately 3,009 full-time employees and is headquartered in Boston, Massachusetts. Haemonetics was founded in 1971.
Market Context & Opportunities
Haemonetics’ diversified medical technology portfolio gives the company exposure to plasma collection, blood management, hospital diagnostics and vascular closure procedures. Its technologies serve multiple clinical environments, from plasma collection centers to operating rooms and critical-care settings.
The recent stock advance was accompanied by trading volume nearly four times the reported average, indicating heightened market activity. However, the supplied data does not identify a specific catalyst behind the October 8 rally, so the price movement cannot be attributed to a particular announcement based on the available information.
Risks & Challenges
Haemonetics’ shares are trading near their 52-week high, and the stock’s trailing P/E ratio of 57.71 makes future operating performance an important consideration for investors.
The company also operates in specialized medical technology markets where product adoption, regulatory requirements, healthcare spending and competition can influence demand. Following the recent price increase, investors may focus on whether upcoming financial results support the stock’s valuation.
Upcoming Earnings
Haemonetics is scheduled to report earnings on November 5, 2026, according to the provided market data. Investors will be watching for updates on the company’s financial performance and demand across its plasma, blood center and hospital technology businesses.
Closing Paragraph
Haemonetics shares closed at $119.47 on October 8, up 17.46%, bringing the stock close to its 52-week high of $121.00. With a market capitalization of approximately $5.44 billion and a portfolio spanning plasma collection, hospital technologies, blood management and vascular closure products, the company remains a notable healthcare technology stock heading into its November earnings report.
